ROCKVILLE, Md., Nov. 2, 2016, RGRX, /PRNewswire/ RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ( the Company or RegeneRx ), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a single unit dosage eye drop formulation containing Thymosin beta 4 (Tβ4). Tβ4 is the active pharmaceutical ingredient in RGN-259, RegeneRx s preservative-free eye drops currently in Phase 3 clinical trials. Claims covered
http://bit.ly/2fEW4ou
No comments:
Post a Comment